VeonGen Therapeutics and the US Food and Drug Administration (FDA) agreed on the design of a pivotal phase 3 trial of VG801 at a Regenerative Medicine Advanced Therapy (RMAT) Type B meeting. VG801 is an investigational dual adeno-associated virus (AAV) gene therapy for Stargardt disease and other ABCA4-associated retinal dystrophies.
The agreement covers the primary end point, study duration, and control arm. It also covers manufacturing: the FDA agreed that the existing clinical batch can be used for the pivotal study, along with parts of the commercial manufacturing strategy.1 The company did not disclose what any of these trial parameters are.
Most programs that have reached late-stage testing in Stargardt disease try to slow atrophy, either by reducing bisretinoid accumulation or by modifying downstream disease pathways. VG801 instead tries to restore full-length ABCA4 in photoreceptors. Of 13 patients with measurable baseline best-corrected visual acuity (BCVA) in the first-in-human study, all improved from baseline to month 6 or month 12. Eleven gained at least 5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, 7 gained at least 10, and 4 gained at least 15.1
Phase 1/2 study design and findings
The phase 1/2 trial (NCT07002398) is a single-arm, open-label, nonrandomized, single-dose-escalation, first-in-human study. It enrolls patients aged 6 years or older with Stargardt disease due to biallelic ABCA4 mutations who receive VG801 at low, medium, or high dose.3 Treatment is a single subretinal injection, and the primary outcome is adverse events and serious adverse events.3 Fifteen patients, including adults and children, have been dosed across the 3 cohorts. The release gives no dose levels, ages, or number of pediatric patients.1
VeonGen also reported sustained improvement through month 12 on a Virtual Reality Visual Test (VRVT) and on microperimetry fixation, with retinal structure described as stable, but it gave no numbers for either measure.1 For safety, the release says only that the profile is "favorable" to date. It lists no specific adverse events and does not address intraocular inflammation.1 An earlier company update, issued when 9 patients had completed 6-month follow-up, said there had been no dose-limiting or serious adverse events.2 Those data were scheduled for an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting.2
VeonGen is developing the VRVT as a functional vision endpoint through the FDA's Rare Disease Endpoint Advancement (RDEA) Pilot Program. VG801 also holds phase 1/2 clinical trial authorizations in Europe and China.1 The RDEA program, established in 2022, supports sponsors developing novel efficacy endpoints for rare disease therapies.7
Clinical context
Stargardt disease type 1 (STGD1) is caused by mutations in ABCA4, which encodes a photoreceptor transporter that clears potentially toxic retinoid by-products of the visual cycle. The company estimates prevalence at about 1 in 8,000 to 10,000 people worldwide.1 No therapy is approved. Management has consisted of low-vision rehabilitation and visual aids.
That may change soon. The FDA has accepted Belite Bio's new drug application for oral tinlarebant, a retinol-binding protein 4 antagonist, and set a Prescription Drug User Fee Act date of February 12, 2027.8 In the phase 3 DRAGON trial, which randomly assigned 104 patients aged 12 to 20 years, tinlarebant reduced lesion growth on definitely decreased autofluorescence by roughly 36% over 24 months.10 Gene-based approaches are also advancing. Ocugen has finished dosing 63 participants in the randomized, masked phase 2/3 GARDian3 trial of OCU410ST, an AAV5-delivered RORA modifier gene therapy given by a single subretinal injection, with untreated patients as controls.9
